PerrigoPRGO
About: Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Employees: 8,379
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
295% more call options, than puts
Call options by funds: $53.3M | Put options by funds: $13.5M
21% more repeat investments, than reductions
Existing positions increased: 137 | Existing positions reduced: 113
9% more funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 12 (+1) [Q1 2025]
9% more capital invested
Capital invested by funds: $3.45B [Q4 2024] → $3.75B (+$306M) [Q1 2025]
0.1% less ownership
Funds ownership: 98.19% [Q4 2024] → 98.09% (-0.1%) [Q1 2025]
3% less funds holding
Funds holding: 353 [Q4 2024] → 342 (-11) [Q1 2025]
14% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 51
Research analyst outlook
We haven’t received any recent analyst ratings for PRGO.
Financial journalist opinion
Based on 7 articles about PRGO published over the past 30 days
